Full Press Release Details
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement.
RAPP
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Key Takeaway: Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Price reaction · baseline $20.85 (2024-06-11 close) · hit after-hours · clean, no other RAPP news in the window
day 0 close
+9%
day 1
+10.6%
day 3 · peak
+21.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+91%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
RAP-219
Phase 3 · Focal Seizure